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were extracted and summarized. RESULTS: The study identi-
ﬁed 16 adverse events associated with blood transfusions in
which incidence rates were reported in the literature for the
time period of 2000 to 2007. Of those, the adverse events with
the highest associated mortality rate were: 1) acute haemolytic
transfusion reactions due to non-ABO compatibility (between
2.11%–7.06%); 2) transfusion-related acute lung injuries
(TRALI) (10% approx); and 3) bacterial sepsis (between 17%–
22%). Reported as incidence rates, the most frequently
reported adverse event was febrile reaction (0.9/1000 by trans-
fusion units) and mild allergic reaction (1/50–1/100 by trans-
fusion units). CONCLUSION: In spite of today’s safety and
quality controls measures for blood transfusions, a considerable
risk of adverse events is still associated with them. Therefore,
alternatives to blood transfusions should be considered when
possible.
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OBJECTIVES: IDA, the most common form of anaemia, has a
relatively high prevalence across Europe. IDA is common in
pregnancy, postpartum and inﬂammatory bowel disease (IBD)
with IDA prevalences of 18, 17 and 33% respectively. At
present, treatment with parenteral iron substitution is limited
by the amount of iron which can be administered intravenously
in any one application. This study estimates the BI associated
with partially substituting the standard i.v. treatment, iron
sucrose, with a new treatment, ferric carboxymaltose, allowing
for the application of higher dosages in a shorter time. The
study adopted the perspective of the Swiss mandatory health
insurance over 3 years covering the indications pregnancy, post-
partum and IBD. METHODS: Resource use was based on
primary data and guidelines. Costs were estimated using a fee-
for-service reimbursement system (Tarmed), including drug, per-
sonnel and other costs. The price of ferric carboxymaltose was
assumed to be that of iron sucrose +40%. The BI was estimated
for the ﬁrst 3 years post-launch, using a substitution rate of
20% in year 1 and 50% in year 2 and 3. RESULTS: Ferric
carboxymaltose reduces the costs per treatment cycle and
patient in IBD by 35% compared to iron sucrose (CHF 475 vs.
CHF 732), due to reduced personnel costs: 1000 mg iron
requires one application with ferric carboxymaltose and 5 for
iron sucrose (200 mg each). Total savings to the Swiss manda-
tory health insurance amount to approx. CHF 1 Mio (approx.
€ 611′600) in year 1 and approx. CHF 2.5 Mio in year 2 and
3 each. Costs were also reduced by 33% in the gynaecological
indication using smaller, empirical dosages of 500 mg. CON-
CLUSION: Treating IDA involves substantial costs to the Swiss
mandatory health insurance. Substitution of iron sucrose by
ferric carboxymaltose may help to reduce these due to saved
personnel costs, despite higher product costs.
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OBJECTIVES: To analyze cost-effectiveness of bortezomib
versus dexamethasone for recurrent or treatment-resistant mul-
tiple myeloma in Russian health care system. METHODS: The
study was performed from the Russian reimbursement system
point of view. An economic model prepared for the submission to
National Institute of Health and Clinical Excellence was used as
a framework. Effect of studied drugs was measured in life-years
gained. The effectiveness was estimated on the basis of APEX
study results and complemented with prognosis of long-term
outcomes. Direct medical costs for medication were included into
the model, registered prices were taken from the Russian reim-
bursement list while dose regimen and number of treatment
courses were considered to be equal to those used in APEX study.
The incremental cost-effectiveness ratio (CER) was calculated.
RESULTS: The incremental effectiveness of bortezomib versus
dexamethasone was estimated as 2,371–2,739 life-years gained
(the interval includes minimal and maximal values identiﬁed by
different approaches to long-term outcomes projection). The
incremental cost was 1 822 774,00 rubles (about 70 thousands
USD). The incremental CER was 67,510,148 — 792,510,43
rubles (25–29 thousands USD) per life-year gained. CONCLU-
SION: The incremental CER for bortezomib is comparable with
other expensive drugs included into the reimbursement system.
Further studies are needed to assess cost-effectiveness of bort-
ezomib vs other therapeutic strategies used for resistant and
recurrent multiple myeloma and to evaluate effectiveness in
medical practice.
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OBJECTIVES: To analyze cost-effectiveness of Ferrum Lek
(Ferrum III) versus Fenuls (Ferrum II) for iron-deﬁcient anemia in
elderly patients with gastrointestinal comorbidy in Russian
health care system. METHODS: Randomized multi-center
study of 132 ambulatory patients (60–86 years old, mean age
69.11  6.39; 102 (77.27%) were females). Criteria for anemia
was decreasing of hemoglobin (Hb) level below 110 g/L. Sixty-
six patients received either Ferrum Lek (200 mg daily) or Fenuls
(200 mg daily). Duration of treatment was 6 weeks. Criteria of
effectiveness were: normalization of Hb level; increasing levels
of Hb and Fe in plasma; adverse effects at day 42 after start
of treatment. The cost-effectiveness ratio (CER) was calculated
(cost of 1 g/L Hb increasing). RESULTS: At follow-up Hb level
increases in Ferrum Lek group was 30.1 g/L (12.3–88.4) and
19.8 g/L (4–39) in Fenuls group. Normalization of Hb level
(110 g/L) was achieved in 62 (93.94%) patients in Ferrum Lek
group and in 53 (80.3%) patients in Fenuls group. Targeted Hb
level (120 g/L) was achieved in 54 (81.82%) patients in Ferrum
Lek group and in 36 (54.55%) patients in Fenuls group. Drop-
outs due to adverse effects were: 1 patient in Ferrum Lek group
and 9 patients in group. Gastrointestinal adverse effects occurred
signiﬁcantly more often in Fenuls group than in Ferrum Lek
group (constipation in 21.2% and 1.5% patients, gastric com-
plaints in 28.8% and 6% respectively). The cost per achieving
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targeted Hb level in Ferrum lek group was 4255.68 rubles and
5990.76 rubles in Fenuls group. Mean cost of 1 g/L Hb increas-
ing is 144.05 (49.8–287.7) rubles with Ferrum Lek and 224.72
(69.61–896.6) rubles with Fenuls. CONCLUSION: Ferrum Lek
is cost-effective medicine for treating iron-deﬁcient anemia in
elderly patients with gastrointestinal co-morbidities in compari-
son with Fenuls.
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OBJECTIVES: To evaluate the cost-effectiveness and Positive
Investment Interval (PII) of ADVATE [Antihemophilic Factor
(Recombinant), Plasma/Albumin-Free Method, PFM] as an
on-demand/prophylactic modality for hemophilia A (HA) treat-
ment compared to the best current Finnish treatment practice
(Kogenate) in a scenario where a pathogen emerges and
is transmitted trough non-PFM methods as the Hepatitis C
virus (HCV) in the 1980’s. METHODS: Incremental cost-
effectiveness analysis was performed using probabilistic simu-
lation to depict uncertainty. Conservative information related
to treatment practices, costs and survival in Finland were gath-
ered from literature and clinical experts. HIV and HBV were
excluded from the modeling, because only 2 HIVs have been
transmitted through coagulant products to Finnish HA patients
and efﬁcient vaccinations against HBV infection exists. Our
innovation, PII, is discussed elsewhere. Here, PII was used to
assess the interval when the extra treatment costs of ADVATE
are compensated by the treatment costs of emerging pathogen
(i.e. interval when no pathogens should emerge, if non-PFM
method is used). RESULTS: Current treatment practice was
dominated by the ADVATE scenario. 18 years old HA male
with and without pathogen transmission had survival estimates
of 48 and 55 years, respectively. The expected difference in
survival was 3.48 years (51% less pathogen transmissions).
Mean treatment cost differences were 7,500–50,200 €/year and
213,700–2,381,600 €/lifetime favoring ADVATE. All PIIs for
annual ADVATE investment favored ADVATE and were 1–7
years depending on patient’s weight, age, and treatment modal-
ity. When production losses and discounting of costs and effec-
tiveness (5%) were included in sensitivity analysis, the relative
differences increased (e.g. PIIs became 1–9 years due to pro-
duction losses). CONCLUSION: ADVATE improves survival, is
cost-effective and offers good long-term investment in the treat-
ment of hemophilia A, when known/unknown pathogens trans-
mitted through non-PFM methods emerge. When investment’s
safety is of concern, PII offers new hands-on interpretation for
the political discussion.
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OBJECTIVES: To conduct a cost per QALY analysis of intrave-
nous versus oral administration of iron, in anemia in Oncology,
Chronic Kidney Disease (CKD) and Post-partum patients.
METHODS: Intravenous iron supplementation has been shown
to improve Hb response to EPO treatment, and to decrease EPO
dosage requirements in patients with chronic anemia. Intrave-
nous iron is more costly but also more effective than oral iron in
treatment of anemia. A Markov model was developed for esti-
mating incremental costs and QALYs in Oncology and CKD
patients. Incremental costs were estimated for iron therapy,
Erythropoietin (EPO) administration, Blood transfusion, and
outpatient visits. QALY gains were estimated by linking Hb
levels to QALY weights. A piggy-back approach was used for
estimating costs and QALYs in anemia treatment in Post-Partum
patients. Swedish prices and data representing Swedish treatment
patterns and patient characteristics are derived from national
databases and publications. RESULTS: In CKD patients, the cost
of intravenous iron is offset by cost savings for EPO. Intravenous
iron successfully corrects the anemia quicker than oral iron,
resulting in a gain of 0.065 QALYs. In Oncology, the cost of IV
iron is also offset by savings in EPO costs. Intravenous iron
corrects the anemia quicker than oral iron and reaches a higher
Hb level, with a resulting gain of 0.0759 QALYs. In post-partum
patients, Hb is more quickly corrected with intravenous iron,
leading to a QALY gain of 0.0086 during a six week time frame.
The incremental cost for intravenous iron is 700 SEK, with a
resulting cost of 68,000 SEK per QALY gained. CONCLUSION:
Intravenous iron is a cost-effective alternative to oral iron, in
treatment of iron deﬁciency anemia in oncology, CKD and post-
partum patients.
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OBJECTIVES: Haemophilia patients with inhibitors character-
istically have high annual drug costs and other health care
related costs. There are essentially three treatment options:
NovoSeven, FEIBA or ITT followed by regular F8 treatment.
Aim: This cost-minimization simulation examines the treatment
costs of NovoSeven versus FEIBA and ITT/F8 for haemophilia
A/B patients with inhibitors. METHODS: The simulation is
based on a standard set of assumptions for an average severe
haemophilia patient. First, primary prophylaxis treatment is
deﬁned by daily treatment on an annual basis of 50 ìG/KG for
NovoSeven and 40 IU/KG for FEIBA. ITT-F8 treatment follows
the Bonn Protocol for ITT at 300 IU/KG followed by F8 at
15 IU/KG. Second, we assume 2 breakthrough bleeds per
month. Third, the patients weight changes each year through-
out a 21 year child-adolescent-manhood life cycle time series
model according to average yearly weight changes for boys in
the standard population. Fourth, costs are based on estimated
average global realised wholesaler purchaser prices in EUROS.
ITT-F8 costs 0.7271 EUROS for an IU/KG. FEIBA costs
1.143216 EUROS for an IU/KG. NovoSeven costs 0.9191
EUROS for an ìG/KG. Costs are also discounted at a rate of
3.5 percent a year over time. RESULTS: Annual N7 costs for a
70 KG patient are 990.662 EUROS per year. Annual FEIBA
costs for a 70 KG patient are 1.168.367 EUROS per year.
Annual ITT treatment is 11.146.504 EUROS and annual F8
treatment costs are 277.679 EUROS. CONCLUSION: Novo
Seven is slightly cheaper compared to FEIBA for certain dosing
regimens. NovoSeven is also cheaper than ITT-F8 for the ﬁrst
6–7 years after treatment begins.
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